Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevacizumab (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Simcere Pharmaceutical

    • Most Recent Events

    • 04 Jun 2024 Results(n=421) focusing on efficacy of Suvemcitug combo with chemo in PROC,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Primary endpoint has been met (Progression free survival(PFS) by blinded independent review committee(BIRC)), according to Simcere Pharmaceutical Group Ltd media release.
    • 04 Jun 2024 According to a Simcere Pharmaceutical Group Ltd media release, announced presentation of the latest data from registrational phase 3 clinical study of suvemcitug for treatment of platinum-resistant ovarian cancer. The findings were shared as a Late-Breaking Abstract (LBA) oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top